December 8, 2023

(NRF2) (ACTIVATOR | ACTIVATORS | ACTIVATION)

Molecular mechanism of nrf2 activation by oxidative stress The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress Natural Nrf2 activators in diabetes […]
December 8, 2023

(AMPK) (ACTIVATOR | ACTIVATORS | ACTIVATION)

AMPK activation: a therapeutic target for type 2 diabetes? AMPK activators–potential therapeutics for metabolic and other diseases AMPK activation, a preventive therapeutic target in the transition […]
December 8, 2023

GSK3 (INHIBITOR | INHIBITORS)

GSK3 inhibitors: development and therapeutic potential The conundrum of GSK3 inhibitors: is it the dawn of a new beginning? Discovery and development of GSK3 inhibitors for […]
December 8, 2023

ANTI OBESITY

Possible anti-obesity therapeutics from nature–A review Anti-obesity drugs: past, present and future Anti-obesity drugs: a review about their effects and safety Anti-obesity action of oolong tea […]
December 8, 2023

PANCREATIC LIPASE INHIBITOR

The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase A new pancreatic lipase inhibitor isolated from the roots of Actinidia […]
December 8, 2023

ATGL

Of mice and men: The physiological role of adipose triglyceride lipase (ATGL) Hints on ATGL implications in cancer: beyond bioenergetic clues Perilipin controls lipolysis by regulating […]
December 8, 2023

CROSS LINK BREAKERS

Advanced glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process Cross-link breakers as a new therapeutic approach to cardiovascular disease […]
December 8, 2023

FNDC5

FNDC5/irisin is not only a myokine but also an adipokine Irisin/FNDC5-An updated review Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway Irisin and FNDC5 in retrospect: […]